We have some good news to share on National Institutes of Health funding for FSHD. As part of the FSH Society’s committee work in Washington, DC, we recently received FY2015 data release on NIH support for the muscular dystrophies and were very pleased to see actual 2015 fiscal year NIH funding support for FSHD research at… Read More »
The FSH Society has awarded $598,242 in research funds from its August 2015 grant submission cycle. Details of the funded projects can be viewed on this page. These proposals received highest marks from our Scientific Advisory Board. They include projects to advance a gene therapy method, study how the DUX4 gene (which causes FSHD) can damage muscles, identify… Read More »
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Saint Louis University’s (SLU) Center for World Health and Medicine, announced that they have entered into three-year agreement to collaborate on the development of small molecule therapeutics for the potential treatment of Facioscapulohumeral Muscular Dystrophy (FSHD).
The FSH Society Board of Directors has elected two new members at its February 2016 meeting. The newly elected directors, George Pollock Jr and Neil Solomon, MD, bring extensive experience in business, finance, medicine and the healthcare industry to help guide the future development of the FSH Society.
Did you hear? The FSH Society has been awarded a grant by Staples Foundation. We plan to use the donation to support public awareness and youth education about FSHD, such as a social media awareness raising scholarship competition administered by the Jain Foundation. Eligible students can compete this spring for the scholarship by posting a fact… Read More »